**Supplementary Fig. 10. Forest plot of the incidence of death with SOF-based DAA drug treatment of patients with decompensated and compensated hepatitis C cirrhosis patients with HCC.** The incidence of death was significantly higher in patients with decompensated hepatitis C cirrhosis than that in compensated patients: 3.1% (95% CI: 1.5–5.0) vs. 0.0% (95% CI: 0.0–0.9), *p*=0.0014. SOF, sofosbuvir; DC, decompensated cirrhosis; CC, compensatory cirrhosis; HCC, hepatocellular carcinoma.

****